[Male osteoporosis: current treatments and future options].
OBJECTIVE
To provide indications for currently approved treatments and future options for male osteoporosis, based on the pathogenetic mechanisms of bone loss in the male sex.


METHODS
Review of the most significant data reported in the literature.


RESULTS
Unhealthy lifestyle habits should be modified. Testosterone replacement is indicated only in patients with diagnosis of hypogonadism. Based on the demonstrated pathogenetic role of estrogen lack in bone loss in men, either low doses of this hormone or selective androgen receptor modulators have been proposed for the treatment of male osteoporosis. Bisphosphonates are the only medications approved by Food and Drug Administration for idiopathic and glucocorticoid-induced osteoporosis in men. As far as anabolic treatments are concerned, there is not agreement on clinical utility of sodium fluoride. Short-term treatment with parathyroid hormone (PTH) seems to be safe and effective in patients with idiopathic osteoporosis, due to its anabolic action. Therapeutic use of growth hormone (GH) and insulin-like growth factor type I (IGF-I), both considered as potential anabolic agents, is still limited because of the high incidence of side effects and relatively transient efficacy, particularly of IGF-I.


CONCLUSIONS
Treatments should be selected on the basis of anti-fracture efficacy of various medications, which has been demonstrated so far only for alendronate and risedronate. Although anabolic agents produce noticeable increase of bone mineral density, is still debated if they also reduce fracture incidence in males with osteoporosis.
Romagnoli
E
E
Ospedale San Giovanni Battista, Università La Sapienza, Roma, Italia.
Paglia
F
F
Dionisi
S
S
De Geronimo
S
S
Pepe
J
J
Di Virgilio
R
R
Minisola
S
S
D000328:Adult; D015519:Bone Density; D004032:Diet; D004164:Diphosphonates / Q000627:therapeutic use; D050723:Fractures, Bone / Q000517:prevention & control*; D005938:Glucocorticoids / Q000009:adverse effects; D013006:Growth Hormone / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000009:adverse effects / Q000627:therapeutic use; D008019:Life Style; D008297:Male; D010024:Osteoporosis / Q000139:chemically induced / Q000150:complications* / Q000188:drug therapy* / Q000209:etiology; D010281:Parathyroid Hormone / Q000627:therapeutic use; D012737:Sex Factors; D012969:Sodium Fluoride / Q000627:therapeutic use
D004164:Diphosphonates; D005938:Glucocorticoids; D010281:Parathyroid Hormone; D007334:Insulin-Like Growth Factor I; D012969:Sodium Fluoride; D013006:Growth Hormone